drugset / Trial / NCT05722171
Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, dose-escalation study to explore the safety, efficacy, and cytodynamic characteristics of the drug, and to initially observe the efficacy of the drug in subjects with relapsed/refractory B7-H3-positive acute myeloid cell line leukemia.
Timeline
- Start
- 2022-12-27
- Primary completion
- 2023-12-27
- Completion
- 2024-12-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UTAA06 | Cell therapy | 1e+08 cells | — |
| Subject | UTAA06 | Cell therapy | 2e+08 cells | — |
| Subject | UTAA06 | Cell therapy | 4e+08 cells | — |